The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues. Methods: We conducted a prevalence-based cost-of-illness study with a societal perspective. Results: The societal costs of dementia in Sweden in 2012 were SEK 62.9 billion (approximately €7.2 billion, approximately US$9.0 billion) or SEK 398,000 per person with dementia (approximately €45,000, approximately US$57,000). By far the most important cost item is the cost of institutional care: about 60% of the costs. In the sensitivity analysis, different quantification and costing approaches for informal care resulted in a great variation in the total societal cost, ranging from SEK 60 billion (€6.8 billion, US$8.6 billion) to SEK 124 billion (€14.1 billion, US$17.8 billion). Conclusions: The societal costs of dementia are very high. The cost per person with dementia has decreased somewhat, mainly because of de-institutionalisation. The majority of the costs occur in the social care sector, but the costing of informal care is crucial for the cost estimates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · cited 1×
“[25], SNAC-Kungsholmen [9], EURODEM [26], Alzheimer Cooperative Valuation in Europe [27], EuroCoDe [28] and Alzheimer’s Disease International [ADI] [3]).”
BackgroundSelf-citationCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Self-citationMonetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · cited 1×
“Studies on potential disease-modifying agents have so far not been successful, although there are still many compounds in clinical development [12, 13].”
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Rocca, W. A., Petersen, R. C., Knopman, D. S., Hebert, L. E., Evans, D. A., Hall, K. S., Gao, S., Unverzagt, F. W., Langa, K. M., Larson, E. B., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.002 · Cited by 498 · cited 1×
“Because there is a discussion currently regarding age-specific dementia prevalence [10], we also present results based on other prevalence sources [3, 8, 9, 24–28] in the sensitivity analysis.”
ResultBrouwer, W. B. F., van Exel, N. J. A., van Gorp, B., & Redekop, W. K. (2006) · Quality of Life Research · doi:10.1007/s11136-005-5994-6 · Cited by 452
Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study
Schrijvers, E. M. C., Verhaaren, B. F. J., Koudstaal, P. J., Hofman, A., Ikram, M. A., & Breteler, M. M. B. (2012) · Neurology · doi:10.1212/wnl.0b013e3182553be6 · Cited by 408
Siegel, J. E., Torrance, G. W., Russell, L. B., Luce, B. R., Weinstein, M. C., & Gold, M. R. (1997) · PharmacoEconomics · doi:10.2165/00019053-199711020-00005 · Cited by 233
Cited by
El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190426 · Cited by 216
“Another report using registry data from the Swedish Social Insurance Agency estimated productivity losses in individuals who were prematurely retired or on sick leave due to a dementia diagnosis [69].”
BackgroundThe economic burden of dementia in low- and middle-income countries (LMICs): a systematic review
Mattap, S. M., Mohan, D., McGrattan, A. M., Allotey, P., Stephan, B. C., Reidpath, D. D., Siervo, M., Robinson, L., & Chaiyakunapruk, N. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2021-007409 · Cited by 182
Dementia prevention: The potential long‐term cost‐effectiveness of the FINGER prevention program
Wimo, A., Handels, R., Antikainen, R., Eriksdotter, M., Jönsson, L., Knapp, M., Kulmala, J., Laatikainen, T., Lehtisalo, J., Peltonen, M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12698 · Cited by 66
Self-citationLeniz, J., Yi, D., Yorganci, E., Williamson, L. E., Suji, T., Cripps, R., Higginson, I. J., & Sleeman, K. E. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12198 · Cited by 24
Metadata
- Authors
- Wimo, A., Jönsson, L., Fratiglioni, L., Sandman, P. O., Gustavsson, A., Sköldunger, A., & Johansson, L.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2016-11-18
- Volume
- 8
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2566748315
- Cited by
- 51
- References
- 9
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care. https://app.cochat.ai/papers/10.1186/s13195-016-0215-9
- The paper
- Wimo, A., Jönsson, L., Fratiglioni, L., Sandman, P. O., Gustavsson, A., Sköldunger, A., & Johansson, L. (2016). The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-016-0215-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.